This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Owens and Minor (OMI)
by David Borun
This medical logistics company made big gains in 2020 - and is poised to keep heading higher.
Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.
AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine
by Zacks Equity Research
AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.
Novartis (NVS) Posts Positive Data From Prostate Cancer Study
by Zacks Equity Research
Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.
AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH
by Zacks Equity Research
NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.
Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?
by Kinjel Shah
Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.
5 S&P 500 Stocks That Zoomed 200% Plus From Pandemic Lows
by Sweta Killa
After touching a low of 2,191 on Mar 23, 2020, the S&P 500 staged a strong comeback and is on track to hit a new milestone of 4,000.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $160.50, marking a +0.29% move from the previous day.
J&J's (JNJ) Multiple Sclerosis Drug Ponesimod Gets FDA Nod
by Zacks Equity Research
J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA
by Kinjel Shah
WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA
Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine
by Zacks Equity Research
Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
by Zacks Equity Research
Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.
A Pureplay ETF on Leisure from SonicShares in the Offing
by Sanghamitra Saha
SonicShares recently filed for an Airlines, Hotels, Cruise Lines ETF.
AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots
by Zacks Equity Research
The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
J&J (JNJ) Outperforms the Industry Year to Date: Here's Why
by Zacks Equity Research
J&J's (JNJ) shares are up this year mainly due to successful development of its COVID-19 vaccine.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $160.42 in the latest trading session, marking a +0.51% move from the prior day.
Air Travel Demand Nears 1-Year High: ETFs to Fly High
by Sweta Killa
According to the latest data from Transportation Security Administration (TSA), about 1.357 million travelers checked in at American airports on Mar 12 - the highest number since Mar 15, 2020.
Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B
by Zacks Equity Research
Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.
J&J (JNJ) COVID-19 Vaccine Gets WHO's Emergency Listing
by Zacks Equity Research
J&J's (JNJ) single-shot COVID-19 vaccine gets Emergency Use Listing by the WHO, which will enable it to supply its vaccine to over 190 countries through COVAX facility.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.
AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data
by Zacks Equity Research
AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.